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Nashville, TN 37232-0615, USAType 1 diabetes affects 20million patients worldwide. Insulin is
the primary and commonly the sole therapy for type 1 diabetes.
However, only aminority of patients attain the targeted glucose
control and reduced adverse events. We tested urocortin 2 gene
transfer as single-agent therapy for insulin deficiency using two
mouse models.Urocortin 2 gene transfer reduced blood glucose
for months after a single intravenous injection, through
increased skeletal muscle insulin sensitivity, increased insulin
release in response to glucose stimulation, and increased
plasma insulin levels before and during euglycemic clamp.
The combined increases in both insulin availability and sensi-
tivity resulted in improved glycemic indices—events that
were not anticipated in these insulin-deficient models. In addi-
tion, urocortin 2 gene transfer reduced ocular manifestations of
long-standing insulin deficiency such as vascular leak and
improved retinal function. Finally, mortality was reduced by
urocortin 2 gene transfer. The mechanisms for these beneficial
effects included increased activities of AMP-activated protein
kinase and Akt (protein kinase B) in skeletal muscle, increased
skeletal muscle glucose uptake, and increased insulin release.
These data suggest that urocortin 2 gene transfer may be a
viable therapy for new onset type 1 diabetes and might reduce
insulin needs in later stage disease.Received 12 September 2019; accepted 7 December 2019;
https://doi.org/10.1016/j.omtm.2019.12.002.
Correspondence: H. Kirk Hammond, Veterans Affairs San Diego Healthcare
System, San Diego, CA 92161, USA.
E-mail: khammond@ucsd.eduINTRODUCTION
Type 1 diabetes (T1D) affects 1.3 million patients in the US with
40,000 new patients annually.1 An estimated 20 million are affected
by T1D worldwide.2 Lifespan is shortened 11–13 years3 due to kidney
and heart disease. Tight glucose control reduces microvascular com-
plications and adverse cardiovascular events.4,5 Insulin therapy is
essential for such patients, but has shortcomings. For example, only
a minority of patients achieve targeted glucose control,5 and aggres-
sive insulin therapy increases serious hypoglycemic episodes, which
shorten life.6 In addition, the majority of T1D patients develop insulin
resistance.7–9 Cardiovascular risk is 2.5-fold higher in T1D patients
with insulin resistance versus those with normal insulin sensitivity.7220 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2
This is an open access article under the CC BY-NC-ND license (httpDespite these shortcomings, insulin remains the sole therapy
currently recommended by the American Diabetes Association10—
and one which has been used for nearly 100 years.11 In the present
study, we tested a new approach to address these shortcomings of
T1D therapy, using rodent models of insulin deficiency.
Recent clinical trials have tested the efficacy and safety of a wide range
of non-insulin agents, used in combination with insulin in T1D, to
improve glycemic control, reduce insulin requirements and weight
gain, and to lessen the frequency of serious hypoglycemic episodes.
A recent review of these clinical trials reveals modest reductions in
HbA1c and daily insulin requirements, but often at a cost of undesir-
able side-effects.12 Only pramlintide has FDA approval as a co-treat-
ment with insulin but it is not widely used. An ideal adjunct to insulin
would reduce insulin needs, require infrequent administration,
reduce weight gain, and favorably affect heart function. Urocortin 2
(Ucn2) gene transfer fulfills these criteria in insulin resistant mice.13
In the present study, we ask whether Ucn2 gene transfer—in the
absence of exogenous insulin—can normalize glycemic control in
two murine models of insulin deficiency.
Gene transfer is justified because there is an unmet medical need for
treating T1D more effectively and in a manner that promotes patient
compliance, and because T1D is associated with high morbidity and
mortality. We propose intravenous (i.v.) delivery of a vector encoding
a transgene with beneficial paracrine and endocrine actions (Fig-
ure 1A). This strategy could enable patients to be treated during an
office visit by a one-time injection of the vector, a feature that would
increase compliance and reduce costs. The best vector to achieve these
goals is adeno-associated virus type 8 (AAV8), encoding Ucn2. Ucn2,
a recently discovered peptide, acts via corticotropin-releasing020 ª 2019 The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Gene Transfer of Peptides with Beneficial
Paracrine and Endocrine Actions: Ucn2 Gene
Transfer
(A) A one-time i.v. injection of an adeno-associated
virus 8 encoding urocortin 2 (AAV8.Ucn2) exploits
paracrine and endocrine actions of Ucn2, which in-
crease glucose disposal, insulin sensitivity, and car-
diovascular function. (B) i.v. delivery of AAV8.mUcn2
(n = 14) or saline (n = 14) to Akita mice. Data obtained
2 months after delivery to 2-month-old mice shows a
9.8-fold increase in plasma Ucn2 (p < 0.0001, Stu-
dent’s t test, unpaired, two-tailed; error bars denote
SE). Vector dose was 2  1013 genome copies/kg, i.v.
in all studies. (C) AAV8.mUcn2 vector map. ITR, in-
verted terminal repeat; CMV.en, human cytomegalo-
virus enhancer; mUcn2, murine urocortin 2; RbGpA,
rabbit beta-globin poly(A). Data are presented as
mean ± SE.
www.moleculartherapy.orghormone type 2 receptors (CRHR2), which are expressed in skeletal
muscle, heart, gastrointestinal tract, vasculature, and brain.14 Studies
in animals and patients with heart failure have shown favorable car-
diovascular effects of brief Ucn2 peptide infusions.15,16
The goal of the present study was to test the efficacy of this new
approach for the treatment of T1D.We used Akita mice, a monogenic
nonobese model of insulin deficiency,17 which is also useful to study
the microcirculatory abnormalities of T1D.18 Confirmatory studies
were conducted in mice rendered insulin deficient by streptozotocin
(STZ). T1D is amajor risk factor for several prevalent life-altering and
life-terminating diseases: peripheral vascular disease, stroke, myocar-
dial infarction, and heart failure. The discovery and development of
more effective therapies that reduce the prevalence of the cardiovas-
cular and microvascular complications associated with T1D is
needed. The goal of the present study was to test a new approach.
Our hypothesis was that Ucn2 gene transfer would, even in the
absence of exogenous insulin, increase glycemic control, and reduce
retinopathy and mortality.
RESULTS
Ucn2 Gene Transfer in Akita Mice
Vector dose (AAV8.Ucn2 and AAV8.Null) was 2 1013 gc/kg, i.v., in
all studies. Plasma Ucn2 was increased 9.8-fold (p < 0.0001) to a mean
value of 11.7 ng/mL (from 1.2 ng/mL) 8 weeks after i.v. delivery of
AAV8.Ucn2 (Figures 1B and 1C). This was associated with pro-
nounced mRNA expression in liver (a 33,000-fold increase) and in
left ventricle (651-fold increase). Significant but smaller increases
were seen in skeletal muscle, kidney, and pancreas (ranging from
10-fold to 59-fold) (Table S1).
Phenotypic and Metabolic Features: Effects of Ucn2 Gene
Transfer
Cumulative food and water consumption, assessed for 2 months
after treatment, were lower in Akita mice that received Ucn2Moleculgene transfer (p < 0.0001 for both; Figures 2A and 2B), but had
not returned to the levels seen in non-diabetic control mice.
Body weight was increased 2 months after Ucn2 gene transfer
(p < 0.0002; Figure 2C), and urine volume was reduced (p =
0.04; Figure 2D). Urine albumin-to-creatinine ratio was reduced
in Akita mice that received Ucn2 gene transfer (p = 0.01; Figure 2E)
but serum creatinine showed no group differences (Figure 2F).
Akita mice showed increased plasma glucagon-like peptide
(GLP-1) compared to normal mice (p = 0.001; Figure 2G). Ucn2
gene transfer increased GLP-1 levels in normal mice (p = 0.03;
Figure 2G), but not in Akita mice. Fasting (basal) plasma glucagon
levels were higher in Akita mice than in control mice (p = 0.001),
but glucagon levels were not altered by Ucn2 gene transfer (Fig-
ure 2H). Plasma leptin concentration was unaffected by Ucn2
gene transfer in either normal mice or in Akita mice (Figure 2I).
Non-fasting plasma triglyceride concentrations were lower in
Akita mice that had received Ucn2 gene transfer (p = 0.0005;
Figure 2J). Metabolic analysis (Table 1) indicated that Akita mice
that received Ucn2 gene transfer showed 10%–11% reductions
in the rates of oxygen consumption (p < 0.0001) and CO2 produc-
tion (p = 0.0004) with no change in the respiratory exchange
ratio. Activity also was reduced in Akita mice after Ucn2 gene
transfer (p = 0.019).
Glucose Disposal
Ucn2 gene transfer reduced fasting (p < 0.0002; Figure 3A)
and random glucose levels (p < 0.0003; Figure 3B) and
was associated with reduced HbA1c (p < 0.005; Figure 3C),
indicating reduced hyperglycemia. There was an enduring benefi-
cial effect of Ucn2 gene transfer on fasting hyperglycemia in
Akita mice, with no evidence of decline for 4 months (p <
0.0001; Figure 3D). In addition, glucose tolerance tests showed
sustained benefits of Ucn2 gene transfer on glucose disposal (p =
0.0006; Figure 3E) and HbA1c (p = 0.047; Figure 3F) 4 months
after treatment.ar Therapy: Methods & Clinical Development Vol. 17 June 2020 221
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Figure 2. Ucn2 Gene Transfer Reduced Polydipsia, Polyuria, Hyperphagia, and Hypertriglyceridemia and Normalized Body Weight in Akita Mice; GLP-1,
Glucagon, and Leptin Were Unchanged after Ucn2 Gene Transfer in Akita Mice
(A and B) Cumulative water and food intake were reduced in Akita mice that received Ucn2 gene transfer. Controls are age-matched male C57BL/6J mice. (C) Body weight
was higher afterUcn2 gene transfer in Akita mice. (D) 3 h urine collection, 2 months after AAV8.Null or AAV8.Ucn2 delivery to 2-month-old Akita mice, showing reduced urine
volume. (E) There was reduced urine albumin-to-creatinine ratio after Ucn2 gene transfer (p = 0.01; repeated twice). (F) Serum creatinine was similar in all three groups. (G)
Plasma GLP-1 was increased following Ucn2 gene transfer in normal control mice (p = 0.03), and Akita mice showed increased plasma GLP-1 versus normal mice (p =
0.001). However,Ucn2 gene transfer in Akita mice had no effect on GLP-1 levels. (H) Plasma glucagon wasmeasured before and 2 h after glucose stimulation (2.5 g/kg, oral).
Fasting (basal) plasma glucagon was higher in Akita mice than in control mice (p = 0.001), but glucagon levels were not altered by Ucn2 gene transfer in Akita mice. Ex-
periments were repeated 3 times. (I) Plasma leptin was unaffected by Ucn2 gene transfer in normal mice or in Akita mice. (J) Non-fasting plasma triglyceride (TG) was lower in
Akita mice that had received Ucn2 gene transfer (p = 0.0005). Akita mice received saline, AAV8.Null or AAV8.Ucn2. Mice were 2–4 months old at the time of vector or saline
delivery except in (D) (6 months old) and data were collected 1–3 months later. (A and B) p value from two-way ANOVA, for gene effect; (C–J) p values from Student’s t test
(unpaired, two-tailed) with Bonferroni correction. Group sizes are indicated in graphs. Data are presented as mean ± SE.
Molecular Therapy: Methods & Clinical DevelopmentHyperinsulinemic Euglycemic Clamp
Blood glucose was matched from 80–120 min of the clamp (Fig-
ure 3G) through a 2.8-fold increase in glucose infusion rate (p <
0.0001; Figure 3H). Akita mice that received Ucn2 gene transfer
showed restoration of insulin-induced whole-body glucose clearance
with reduced fasting total body glucose disappearance (p < 0.004; Fig-
ure 3I), increased insulin-induced change in rate of disappearance
(Rd) (p = 0.004; Figure 3J), reduced hepatic glucose production before
(p = 0.008) and during the clamp (p = 0.02; Figure 3K), and increased
skeletal muscle glucose uptake (Figure 3L) in gastrocnemius (p =
0.004) and vastus lateralis (p < 0.0002).
Insulin Release
We next assessed glucose-stimulated insulin release in 5-month-
old Akita mice, 2 months after vector delivery. Mice that received222 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2AAV8.Null had fasting plasma insulin levels 87% lower
(0.12 ng/mL) than normal (C57BL/6J) mice and were similar to
reduced insulin levels previously reported in Akita mice.19,20
Importantly, Akita mice that received AAV8.Null exhibited a flat
insulin response to oral glucose stimulation (Figure 4A). Akita
mice that received AAV8.Ucn2, in contrast, showed increased
plasma insulin (p < 0.0001), reaching 3-fold higher levels than
those seen in mice that received AAV8.Null (p = 0.008) 120 min
after glucose administration. Peak insulin concentration was
lower than what is seen in normal mice but was sufficient to
reduce fasting and random glucose, reduce HbA1c, and increase
glucose tolerance (Figures 3A–3F). In addition, Akita mice that
had received Ucn2 gene transfer had higher plasma insulin levels
before and 100–120 min after initiation of hyperinsulinemic
euglycemic clamps (Figure 4B). Despite higher levels of plasma020
Table 1. Metabolic Parameters
Control Akita
Saline (6) Ucn2 (6) % D p Value Saline (6) Ucn2 (6) % D p Value
Energy, Kcal/h 0.51 ± 0.02 0.58 ± 0.02 13 <0.0001 0.54 ± 0.02 0.53 ± 0.02 1.7 0.2
VO2, ml/kg/h 3,450 ± 101 3,520 ± 94 2 ns 4,646 ± 143 4,129 ± 117 11 <0.0001
VCO2, ml/kg/h 3,243 ± 119 3,347 ± 118 3 ns 4,363 ± 183 3,936 ± 135 10 0.0004
RER 0.94 ± 0.01 0.95 ± 0.01 1 ns 0.96 ± 0.01 0.95 ± 0.01 0.14 ns
Activity 117 ± 14 136 ± 15 16 0.005 178 ± 18 151 ± 20 15 0.019
Metabolic effects ofUcn2 gene transfer in Akita mice. Control mice (C57BL/6J) and Akita mice (2 months old, male) received saline orUcn2 gene transfer, and metabolic data collected
2 months later for 6.5 days. Energy expenditure is the heat derived using the formula: 3.815 + 1.23  RER  VO2. VO2, rate of oxygen consumption. VCO2, rate of carbon dioxide
production. RER, respiratory exchange ratio. Activity represents horizontal ambulatory motor activity. Data are mean ± SE. p values are from Student t test (unpaired, two-tailed).
www.moleculartherapy.orginsulin during the glucose clamp studies, insulin levels were
increased proportionately in both groups (Saline-Akita, 5.2 ±
0.9-fold pre-infusion insulin; Ucn2-Akita, 4.2 ± 0.5-fold pre-infu-
sion insulin; p = 0.41). We also examined the effects of Ucn2 gene
transfer in insulin tolerance tests. Ucn2 gene transfer was associ-
ated with increased glucose disposal in response to insulin (p <
0.001; Figure 4C). Thus, Ucn2 gene transfer increases insulin
release and insulin effectiveness in vivo. Finally, to determine
whether Ucn2 had a direct effect on islet insulin secretion, we per-
formed studies in isolated islets. Normal mice received i.v. saline
versus AAV8.Ucn2 with subsequent islet isolation, and evaluation
of glucose-stimulated insulin release. The incubation of isolated is-
lets with Ucn2 peptide (200 nM) increased insulin secretion from
islets, whether isolated from mice that had received Ucn2 gene
transfer or saline (Figure 4D). This confirmed that Ucn2 peptide
directly increases glucose-stimulated islet insulin release. These
data provide a mechanism for increased glucose-stimulated insulin
release in Akita mice that received Ucn2 gene transfer (Figures 4A
and 4B). There were no group differences in basal or Ucn2
peptide-stimulated islet somatostatin release at low or high glucose
levels.
Diabetic Retinopathy
Next, we asked whether Ucn2 gene transfer attenuates retinopathy
in Akita mice. Akita mice (4 months old) received saline (n = 5) or
AAV8.Ucn2 (n = 4) and underwent fluorescein angiography 3months
later. Retinal vascular leak was lower in Akita mice that had received
Ucn2 gene transfer (19% ± 5% versus 43% ± 1%; a 56% relative reduc-
tion; p = 0.001; Figures 5A and 5B). Normal 6-month-old C57BL/6J
mice show retinal vascular leak of 16% ± 3%.21 A functional evalua-
tion by electroretinography, which measures the electrical response of
the retina to flashes of light, confirmed improved retinal function
following Ucn2 gene transfer. Scotopic b-wave response amplitude,
corresponding to light-induced activity of the primary rod system,
improved >80% following treatment, recovering to levels comparable
to normal mice (p = 0.02; Figure 5C).
Mortality
34 Akita mice (2.5 months old) were randomized to receive i.v. sa-
line (n = 17) or Ucn2 gene transfer (n = 17). Mice that receivedMoleculUcn2 gene transfer showed decreased mortality—3 of 17 (18%) of
these mice had died 7 months after gene transfer as compared to
16 of 17 (94%) in saline-treated Akita mice (p < 0.0001; Figure 5D).
Previous studies have attributed early mortality to extreme
hyperglycemia.19
Streptozotocin Model of Insulin Deficiency
We then asked whether Ucn2 gene transfer would be effective in a
second model of T1D, using STZ to induce an insulin-deficient
state.22 We found that 5 consecutive daily doses of STZ provided
a stable model of insulin deficiency 3 weeks later. Ucn2 gene transfer
was associated with persistent reductions in fasting glucose (p <
0.005; Figure 5E), reduced AUC in glucose tolerance tests (p =
0.005; Figure 5F), and reduced HbA1c 4 weeks after treatment
(p < 0.003; Figure 5G). These data indicate that the beneficial effects
of Ucn2 gene transfer on insulin deficiency are not model-limited.
We saw a reduction in glucose-stimulated plasma insulin levels
7 weeks after STZ administration (p < 0.0001; Figure 5H), confirm-
ing that STZ in the doses and frequency used was associated with
reduced plasma insulin levels.
LV Function
Akita mice randomized to i.v. AAV8.Null or AAV8.Ucn2 at 6 weeks
of age (hyperglycemia and insulin-deficient present) underwent
echocardiography 10 weeks later. Echocardiography showed
increased ejection fraction and velocity of circumferential fiber
shortening, reductions in end-systolic and end-diastolic dimension
(Table 2). Similar changes were seen in control mice after Ucn2
gene transfer.23
Skeletal Muscle Insulin Signaling
The mechanisms for beneficial effects of Ucn2 gene transfer include
both increased islet insulin release and increased insulin sensitivity
in skeletal muscle. We therefore examined relevant signaling path-
ways, including activation of adenosine monophosphate activated
protein kinase (AMPK) and Akt (protein kinase B) in skeletal muscle
from Akita mice. Ucn2 gene transfer was associated with increased
phosphorylation of Akt at Ser308 (p = 0.005; Figure 6A) and at
Ser473 (p = 0.005; Figure 6A). In addition, Akita mice that had
received Ucn2 gene transfer showed higher levels of skeletal musclear Therapy: Methods & Clinical Development Vol. 17 June 2020 223
A B C D
E F G H
I J K L
Figure 3. Ucn2 Gene Transfer Provided Sustained Increases in Glucose Disposal and Skeletal Muscle Insulin Sensitivity
(A–C) Glucose disposal. Akita mice received AAV8.Ucn2 or AAV8.Null (C57BL/6J; Con). (A and B) 1month later, 12 h fasting glucose (A; p < 0.0002) and random glucose (B;
p < 0.0003) were lower after Ucn2 gene transfer. (C) HbA1c, measured 2.5 months after treatment, was reduced after Ucn2 gene transfer (p < 0.005). (D–F) Duration of
effects. (D) Beneficial effects of Ucn2 gene transfer on fasting glucose 1–4 months after treatment (p < 0.0001, two-way ANOVA). (E) Increased glucose disposal 4 months
after treatment (p = 0.0006; AUC analysis from glucose tolerance test 0–120 min after glucose, 2 g/kg, i.p). (F) HbA1c was reduced 4 months after Ucn2 gene transfer (p =
0.047; two-way ANOVA, Ucn2 effect). (G–L) Hyperinsulinemic-euglycemic clamp. Akita mice received i.v. saline or i.v. AAV8.Ucn2 and underwent clamp 4 months later. (G)
Blood glucose was matched during the clamp (80–120 m). (H) The glucose infusion rate required to maintain similar glucose concentrations was higher (2.8-fold; p < 0.0001,
two-way ANOVA) in Akita mice that received Ucn2 gene transfer, indicating increased insulin sensitivity. (I) 5 h fasting glucose flux (rate of disappearance, Rd) was lower in
Akita mice that had receivedUcn2 gene transfer (p < 0.004). (J) The change in glucose disposal (clampminus basal) was increased in Akita mice that had receivedUcn2 gene
transfer (p = 0.004). (K) Ucn2 gene transfer reduced basal (p = 0.008) and insulin-stimulated hepatic glucose production (HGP; p = 0.02). (L) Ucn2 gene transfer increased
glucose uptake in gastrocnemius (Gastroc; p = 0.004) and vastus lateralis (Vast Lat; p < 0.0002). Mice were 2–2.5 months old at the time of vector or saline delivery, and data
were collected 1–4 months later. (A–C, E, I–L) Student’s t test (unpaired, two-tailed) with Bonferroni correction in (A)–(C), (K), and (L); (D and H): ANOVA. Group sizes are
indicated in graphs. Data are presented as mean ± SE.
Molecular Therapy: Methods & Clinical DevelopmentAMPK activation (p = 0.036; Figure 6B). Ucn2 gene transfer did not
alter skeletal muscle Akt phosphorylation at Ser473 or AMPK activity
in normal mice (Figure 6C).
Skeletal Muscle, Liver, and Pancreas mRNA Expression
There were only 2 instances in which Ucn2 gene transfer was asso-
ciated with >3-fold changes in gene expression in skeletal muscle,
liver, or pancreas that also were statistically significant: liver
fibroblast growth factor 21 (FGF21) (5.1-fold increase, p < 0.01)
and liver Ucn2 (>30,000-fold increase; p = 0.003) (Tables S2–S5).
The increase in Ucn2 expression was expected, but increased
FGF21 expression was not. We measured plasma FGF21 concen-
trations in 4-month-old male control mice (C57BL/6J) and Akita
mice, 2 months after Ucn2 gene transfer, and found increases in
plasma FGF21 in Akita mice (3.9-fold increase; p = 0.026) (Fig-224 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2ure 6D) and confirmed increased liver FGF21 expression (p <
0.013; Figure 6D).
Necropsy and Histology
Necropsy (Table S6) was performed on Akita mice and C57BL/6J
mice with and without Ucn2 gene transfer. Group differences were
observed only in body weight, which was increased in Akita mice
that had received Ucn2 gene transfer (p = 0.0003). Histological in-
spection of liver and LV showed no group differences in fibrosis,
and fatty infiltration in the liver was minimal and similar between
groups (Figure S1). No inflammatory infiltrates were seen. Kidney
histology did not show increased mesangial expansion in Akita
mice compared to control mice, and no group differences were seen
in other histological features. Pancreata showed similar degrees of
fibrosis (Figure S1A). A 3.3-fold increase in islet number was seen020
A B C
D
Figure 4. Effects of Ucn2 Gene Transfer on Insulin Release and Insulin Tolerance
(A) In vivo insulin release. Akita mice received AAV8.Null or AAV8.Ucn2 (n = 8 both group); 2 months later, after 12 h fast, glucose (2.5 g/kg p.o.) was given and plasma insulin
measured. Ucn2 gene transfer increased insulin release (p < 0.0001, gene effect, two-way ANOVA); post hoc p values (p = 0.006 at 60 min; p = 0.008 at 120 min)
from Student’s t test with Bonferroni correction. (B) Plasma insulin levels during glucose clamp. Akita mice that had received Ucn2 gene transfer showed increased plasma
insulin levels before (p = 0.0004) and 100–120 min after initiation of the clamp (p = 0.0006; n = 6–8 per group); Student’s t test with Bonferroni correction. (C) Insulin tolerance
test. Akita mice received AAV8.Null or AAV8.Ucn2 (n = 6 both groups); 2 months later, nonfasted mice received insulin (0.75 U/kg, i.p.) and blood glucose was assessed.
Ucn2 gene transfer was associatedwith increased insulin-induced glucose disposal (p < 0.001). Group sizes are indicated in graphs. (D) Glucose-stimulated insulin secretion,
normal mice. C57BL/6J male mice (2 months old) received i.v. saline (n = 8) or i.v. AAV8.Ucn2 (n = 8), and islets were isolated 1.5 months later. Each data point represents
pooled islets from each of 2 mice within the group. In all instances, high glucose concentration (28 mM) stimulated more insulin release than low glucose concentration
(2.8 mM), as expected. When islets were incubated with Ucn2 peptide (200 nM, 1 h), insulin release was greater than when incubated without peptide, at low and
high glucose concentrations, and whether or not mice had received Ucn2 gene transfer. p values from Student’s t test (unpaired, two-tailed) with Bonferroni correction. Data
are presented as mean ± SE.
www.moleculartherapy.orgin Akita mice that had received Ucn2 gene transfer versus saline (Fig-
ure S1B; p = 0.04); mean islet size was similar between groups.
Compared with normal C57BL/6J mice, reductions in islet insulin
intensity were seen, as expected in Akita mice (data not shown),
with no group difference between saline and Ucn2 gene transfer
(Figure S1C; p < 0.12).
DISCUSSION
The present study shows that Ucn2 gene transfer improves glycemic
control and reduces retinopathy and mortality in insulin deficiency
(Figures 3, 4, and 5)—in the absence of exogenous insulin therapy.
Ucn2 gene transfer increases insulin-stimulated glucose uptake in
skeletal muscle and improves insulin-induced suppression of hepatic
glucose production (Figure 3) yet does not cause hypoglycemia. In the
Akita model of insulin deficiency, despite an 87% reduction in plasma
insulin compared to normal C57BL/6J mice, Ucn2 gene transfer
improved glycemic control, often to normal levels, in the absence of
insulin treatment (Figure 3) by increasing both insulin release and in-
sulin sensitivity (Figures 3 and 4). We also found that Ucn2 gene
transfer was effective in improving disordered glucose disposal in
the STZ model of insulin deficiency (Figure 5), indicating that the
therapy is not model-dependent.Ucn2 gene transfer improves glucose
metabolism to an extent that it renders glucose fluxes (Rd, HGP) in
insulin-deficient Akita mice indistinguishable from glucose fluxesMoleculobserved in normal C57BL/6J mice in glucose clamp studies.24 In
addition to benefits on insulin sensitivity, Ucn2 gene transfer
increased insulin release. For example, we saw increases in plasma in-
sulin in responses to glucose stimulation (Figure 4A), and increased
plasma insulin levels before and 100–120 min after initiation of
the clamp (Figure 4B). We showed that Ucn2 directly stimulates islet
insulin release (Figure 4D). The combined effects of increased insulin
availability and increased insulin sensitivity result in normalization
of glycemic indices, substantial reduction of retinopathy and
increased survival. We found that Ucn2 gene transfer had enduring
effects on glycemic control 4 months after a single administration
and reduced cumulative mortality 7 months after therapy. Ucn2
gene transfer was not associated with differences in GLP-1 or
glucagon in Akita mice, suggesting that incretin signaling did not
play a major role in its beneficial effects on glucose disposal.
Our findings were unexpected. We previously reported resolution
of disordered glucose homeostasis by Ucn2 gene transfer in type 2
diabetes,13 where endogenous insulin is abundant and themechanism
of Ucn2 action was increased skeletal muscle insulin sensitivity. How-
ever, the primary problem in T1D is insulin deficiency—a problem
unlikely to be resolved by anything but exogenous insulin. Indeed,
previous efforts to achieve superior glucose control in T1D with insu-
lin sensitizing drugs have been relatively ineffective.12 ThatUcn2 genear Therapy: Methods & Clinical Development Vol. 17 June 2020 225
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Figure 5. Ucn2 Gene Transfer Reduced Diabetic Retinopathy and Mortality in Akita Mice, and Effects on Glucose Disposal Were Also Seen in a Second
Model of Insulin Deficiency
(A–C) Retinopathy. Akita mice (4 months old) received saline (n = 5) or Ucn2 gene transfer (n = 4) and underwent retinal imaging 3 months later. (A) Fluorescein angiography
was performed to quantitate retinal vascular leak. (B) The graph shows the mean values of both eyes from each of 9 mice. Ucn2 gene transfer reduced vascular leak (p =
0.001). (C) Electroretinography indicated improved retinal function (p = 0.02). (D) Mortality. 34 Akita mice (2.5 months old) received i.v. saline (n = 17) or AAV8.Ucn2 (n = 17).
Ucn2 gene transfer increased survival (p < 0.0001). (E–G) Glucose disposal after Ucn2 gene transfer in a second model of insulin deficiency: streptozotocin (STZ)-treated
mice. (E) 2-month-old male control mice (C57BL/6J) received STZ and randomized 3 weeks later to receive saline orUcn2 gene transfer. Studies to assess glucose disposal
were conducted weekly. Control mice (C) received no STZ or AAV8.Ucn2. 12 h fasting glucose levels showed persistent reduction after Ucn2 gene transfer versus saline in
STZ-induced insulin deficient mice (two-way ANOVA, p < 0.005, Ucn2 effect). Fasting glucose returned to levels similar to control mice. (F) Similar improvements in glucose
tolerance (2 g/kg glucose, i.p.) were seen after Ucn2 gene transfer in STZ-treated mice (two-way ANOVA, p = 0.005, Ucn2 effect). (G) We measured HbA1c 4 before STZ-
treatment and again 4 weeks after Ucn2 gene transfer, which confirmed sustained glycemic control (two-way ANOVA, p < 0.003, Ucn2 effect). (H) Blood was obtained 2 h
after glucose stimulation (2 g/kg, i.p.) before (pre) and 7 weeks after the final dose of STZ. Plasma insulin, as anticipated, was reduced after STZ administration (p < 0.0001);
Student’s t test (paired, two-tailed). p values in (B), (C), and (H) from Student’s t test (unpaired, two-tailed); (D) Kaplan-Meier analysis; (E–G) from two-way ANOVA. Group
sizes are indicated in graphs. Data are presented as mean ± SE.
Molecular Therapy: Methods & Clinical Developmenttransfer normalized glucose disposal despite marked reduction in in-
sulin levels underscores its therapeutic potential in T1D.
The microvascular complications of T1D are tightly linked with de-
gree of glucose control. Retinopathy is a major cause of diabetes-
related blindness. Consistent with previous investigations of age-226 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2matched Akita mice,18,21 eyes of untreated Akita mice showed signs
of diabetic vascular damage such as vascular leakage and new vascular
beds. The significant reduction in retinal vascular leak (Figures 5A
and 5B) in Akita mice that had received Ucn2 gene transfer is a
promising finding vis-à-vis potential therapy for the prevention and
treatment of early clinical diabetic retinopathy. Prolonged vascular020
Table 2. LV Size and Function
Control Akita
AAV8.Null (6) AAV8.Ucn2 (6) p Value AAV8.Null (8) AAV8.Ucn2 (8) p Value
EF, % 66 ± 2 79 ± 2 0.0001 65 ± 2 79 ± 2 <0.001
EDD, mm 3.8 ± 0.1 3.5 ± 0.1 0.03 3.8 ± 0.1 3.5 ± 0.1 <0.04
ESD, mm 2.5 ± 0.1 1.8 ± 0.1 0.0003 2.4 ± 0.1 1.9 ± 0.1 <0.001
VCFc, circ/s 23 ± 1 34 ± 2 0.0003 23 ± 1 34 ± 1 <0.0001
HR, bpm 566 ± 11 550 ± 8 0.25 549 ± 8 547 ± 7 0.9
Effects of Ucn2 gene transfer on left ventricular size and function in Akita mice. Control mice (C57BL/6J) and Akita mice (2 months old, male) received AAV8.Null (as controls) or
AAV8.Ucn2 (2 1013 gc/kg, i.v.), and echocardiography was performed 3–4months later. In both control and Akita mice, gene transfer increased ejection fraction (EF) and the velocity
of circumferential fiber shortening (VCFc, corrected for HR), a measure of left ventricular contractility. Left ventricular end-diastolic and end-systolic diameters were reduced (EDD,
ESD). Heart rate (HR) showed no group difference. Ucn2 gene transfer increased systolic function similarly in normal and in Akita mice. Data are presented as mean ± SE. p values are
from Student t test (unpaired, two-tailed).
www.moleculartherapy.orgleakage can lead to adverse effects on the health and function of
retinal cells. Functional studies indicated that the observed anatomic
differences after Ucn2 gene transfer translate to improved retinal
function (Figure 5C). The extent of beneficial effect of the Ucn2
gene transfer is superior to other systemic treatments of diabetic
retinopathy.4,25,26
Finally, we saw reduced mortality in the present study (Figure 5D).
The deaths were unwitnessed and likely related to metabolic derange-
ment.19 At 9 months (7 months after gene transfer), we saw reduced
mortality in Akita mice that had received Ucn2 gene transfer (Akita +
Ucn2: 18% mortality; Akita + saline: 94% mortality; p < 0.0001; Fig-
ure 5D). Urine albumin-to-creatinine ratio was reduced in Akita mice
after Ucn2 gene transfer (p = 0.01; Figure 2E) but serum creatinine
was unchanged (Figure 2F) and kidney histology (Figure S1) did
not show group differences in mesangial expansion, the hallmark
lesion in diabetic nephropathy. Nephropathy in the Akita mouse de-
pends upon what line the Ins2Akita line is crossed with, and C57BL/6J
tends to have minimal renal abnormalities.20,27
The physiological mechanisms by which Ucn2 gene transfer affects
glucose disposal resides primarily in its augmentation of skeletal mus-
cle insulin sensitivity and subsequent glucose uptake in Akita mice,
effects which were shown in hyperinsulinemic euglycemic clamp
studies (Figures 3G–3L). In addition, in Akita mice, Ucn2 gene trans-
fer increased insulin release in vivo (Figure 4), owing to a direct effect
of Ucn2 on islet insulin secretion (Figure 4D). Importantly, insulin’s
stimulation of whole-body glucose clearance was restored. Finally,
we saw reduced hepatic glucose production after Ucn2 gene transfer
in Akita mice before clamp. During clamp, hepatic glucose produc-
tion was reduced by 78%, an absolute reduction of 14.2 mg/kg/min.
These data indicate increased hepatic insulin sensitivity. But the key
group difference was in skeletal muscle, which became a significant
contributor to glucose homeostasis after Ucn2 gene transfer.
Insulin action involves increased activation of Akt and AMPK, which
promotes Glut4 translocation to the plasma membrane and subse-
quently increases glucose disposal. In skeletal muscle from Akita
mice that received Ucn2 gene transfer, we saw increased Akt phos-Moleculphorylation (Figure 6A) at both Ser473 (p = 0.005) and Ser308 (p =
0.005). Additionally, this was associated with increased AMPK
phosphorylation at Thr172 (p = 0.036; Figure 6B). Akt and AMPK
activation in skeletal muscle were associated with similar increases
in skeletal muscle glucose uptake in vivo in Akita mice that had
received Ucn2 gene transfer (Figure 3L). In contrast to Akita mice,
Ucn2 gene transfer did not affect Akt or AMPK activity in skeletal
muscle from C57BL/6J mice (Figure 6C). Finally, we showed that
Ucn2 gene transfer increases basal and glucose-stimulated insulin
release and insulin-induced glucose disposal in vivo in Akita mice
(Figures 4A–4C). This reflects increased Ucn2-stimulated islet insulin
release, which we demonstrated in isolated islets (Figure 4D). Thus,
Ucn2 peptide directly stimulates islet insulin release, and, even
when plasma Ucn2 is substantially and chronically elevated in vivo
by Ucn2 gene transfer, isolated islets still respond to stimulation by
Ucn2 peptide, indicating that islets do not become refractory to
Ucn2-stimulated insulin secretion.
A previous study reported that Ucn3 peptide reduced glucose-stimu-
lated islet insulin release due to Ucn3-CRHR2 activation on islet delta
cells, which increased somatostatin release, which, in turn, reduced
beta cell insulin release.28 We found that Ucn2 peptide has the oppo-
site effect—glucose-stimulated islet insulin release was increased
(Figure 4D), and there was no change in somatostatin release. Both
peptides bind CRHR2 with similar affinities. However, unlike the
case with Ucn3, islet somatostatin levels were unchanged by Ucn2
peptide. We speculate that the difference may reflect an inverse
agonist effect of Ucn2, which may impede Ucn3’s normal effects on
CRHR2-mediated somatostatin release from delta cells. Testing this
will require studies in delta-cell specific CRHR2-deleted mice. Delin-
eating the molecular basis for this difference in action of Ucn2 versus
Ucn3 on islet insulin release is a focus of ongoing studies in our
laboratory.
Our data indicate that there are two keymechanisms for the beneficial
effects of Ucn2 gene transfer in Akita mice: (1) increased Akt and
AMPK activation leading to increased skeletal muscle glucose uptake;
and (2) increased insulin release from islets. These actions are directly
dependent upon increased plasma levels of Ucn2 peptide, and arear Therapy: Methods & Clinical Development Vol. 17 June 2020 227
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Figure 6. Ucn2 Gene Transfer: Effects on Skeletal Muscle Akt Activation and Plasma Concentrations of FGF21
(A and B) Akita mice (2 months old) received AAV8.Ucn2 or AAV8.Null, and assessment was performed 3 months later. Quadriceps femoris muscle from animals that had
received Ucn2 gene transfer showed increased activities of Akt (Ser-308, p = 0.005; Ser473, p = 0.005; repeated 3 times each) and AMPK (Thr172, p = 0.036; repeated 4
times). (C) Control mice (C57BL/6J), 2.5 months old, received i.v. saline or AAV8.Ucn2, and assessment was performed 1 month later. In contrast to Akita mice, in control
mice, Ucn2 gene transfer did not affect activities of Akt or AMPK. Experiments repeated 2 times. (D) Control and Akita mice (2 months old) received i.v. saline or AAV8.Ucn2
and FGF21 expression assessed 2 months later. Liver FGF21 mRNA expression was increased 5.1-fold (left panel, p < 0.013). Ucn2 gene transfer did not increase plasma
FGF21 concentration in control mice (p = 0.12), but a 3.9-fold increase in plasma FGF21 was seen after Ucn2 gene transfer in Akita mice (right panel, p = 0.026). (A–D)
Student’s t test (unpaired, two-tailed) with Bonferroni correction in (D); group sizes are indicated in graphs. Graphs display data normalized to total Akt (A), vinculin (B), or
GAPDH (C) as shown. Data are presented as mean ± SE.
Molecular Therapy: Methods & Clinical Developmentmediated through Ucn2’s cognate receptor, CRHR2, which is ex-
pressed in skeletal muscle.14We previously showed that Ucn2 peptide
increases Glut4 translocation as effectively as insulin in skeletal
myotubes via AMPK activation.13 The favorable effects of Ucn2
gene transfer on glucose disposal are mediated through CRHR2, since
deletion of this receptor prevents these effects.13
Ucn2 gene transfer increased liver expression of FGF21 in Akita
mice (p < 0.013; Figure 6D), and increased plasma FGF21 concen-228 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2tration in Akita mice (p = 0.026; Figure 6D). FGF21 has beneficial
effects in animal models of diabetes, obesity, and lipid metabolism
and has been proposed as a potential clinical therapeutic in meta-
bolic disorders.29 It may be of mechanistic importance in Ucn2’s
effects on glucose disposal, although FGF21 effects are on adipo-
cytes and increased insulin sensitivity in liver—Ucn2’s effects, in
contrast, are on insulin sensitivity in skeletal muscle. A recent
study showed beneficial effects of FGF21 gene transfer in type 2
diabetes,30 but long-acting FGF21 formulations have not been020
www.moleculartherapy.orgeffective in lowering glucose in clinical trials, although they appear
to reduce weight.31
The Akita and STZmodels of insulin deficiency each have advantages
and disadvantages. Insulin deficiency in Akita mice results from
apoptotic destruction of islet beta cells because of abnormal insulin
folding due to a point mutation in Ins2. Residual insulin production
(10% of normal), persists for several months,17 enabling long term
studies of therapeutic interventions. Although homozygous mice
die early, heterozygotes have sufficient lifespans for studies of 6–
7 months.19 Female Akita mice develop less severe hyperglycemia,
so males are generally used. Likewise, although STZ is an effective islet
toxin in male mice, it does not have an equivalent effect in females.
Therefore, the present studies were, by necessity, limited to male
mice. WillUcn2 gene transfer be effective in females? We have shown
previously that Ucn2 gene transfer increases insulin sensitivity and
normalizes glucose disposal equally well in male and female db/db
mice,13 and that Ucn2 gene transfer increases plasma Ucn2 levels in
a dose-related manner in normal male and female mice (unpublished
data). In addition to an 87% reduction in plasma insulin and a flat
insulin response to glucose, Akita mice showed insulin resistance.
Glucose flux analysis during the clamp showed that untreated Akita
mice exhibited liver and peripheral insulin resistance, which was
also documented in a previous study.32 Studies in STZ-induced insu-
lin-deficient mice demonstrated similar beneficial effects of Ucn2
gene transfer on glycemic indices to those found in the Akita model
(Figure 5), indicating that the benefits ofUcn2 gene transfer in insulin
deficiency is not model-limited. Although both Akita and STZ are
reliable models that mimic the metabolic features of clinical T1D,
they do not involve an autoimmune etiology to insulin deficiency as
seen in clinical T1D. However, Ucn2 gene transfer is not proposed
as a means to prevent the autoimmune effects that lead to islet
destruction, but rather as a treatment for impaired glucose disposal
once present, regardless of etiology.
Crossbreeding leptin-expressing transgenic mice and Akita mice
yielded improved glycemic indices and reduced mortality.19 Howev-
er, the generation of a transgenic cross is not a viable clinical therapy
option, and leptin therapy (metreleptin peptide administration) was
not effective in a subsequent T1D clinical trial.33 In the present study,
plasma leptin concentration was unaltered by Ucn2 gene transfer.
Insulin gene transfer has been used to circumvent the difficult dosing
requirements otherwise required for insulin use. Although such ef-
forts have been successful,34,35 hypoglycemia has been problematic,34
and no clinical trials using this approach have been initiated. Pancreas
or islet transplantation, which are effective, require life-long immuno-
suppression, which, in addition to other problems, compromises
kidney function. Consequently, islet transplantation currently is not
suitable for a majority of patients.36 Stem-cell approaches can circum-
vent problems associated with immunosuppression, and preclinical
studies have shown the efficacy of cell-based therapy for insulin defi-
ciency.37 However, large randomized trials have not been conducted.
Ucn2 gene transfer could forestall the need for islet transplantation or
stem cell therapy, and, once performed, could promote insulin releaseMoleculfrom transplanted or newly formed islets and increase insulin’s
effectiveness.
Based on the present data, we speculate that, in clinical settings, Ucn2
gene transfer might increase insulin effectiveness and reduce insulin
requirements, potentially achieving better glucose control while
reducing insulin’s adverse effects. It would be applicable as a sole
therapy in patients with residual islet function, and as a co-therapy
with exogenous insulin in those with more advanced disease. The
proposed therapy is a one-time i.v. injection, circumventing daily
or weekly dosing, a unique and desirable feature for patients and
clinicians. Because of its beneficial effects on cardiac function, it is
anticipated to reduce cardiomyopathy associated with T1D and
to be particularly effective in patients with diabetes and concomitant
heart failure. AAV8 vectors, in general, at the doses we would propose
based on the current studies, have been well-tolerated in non-human
primate and clinical trials.38–40 i.v. delivery of AAV8.Ucn2 provides
sustained elevation in plasma Ucn2.13,23,41 Pre-existing anti-AAV8
antibodies are not as prevalent in humans (19%) as are AAV1 and
AAV2 (50%–59%).42
In summary, Ucn2 gene transfer may be a viable therapy both for
new onset T1D with detectable endogenous insulin, and for later
stage T1D to reduce exogenous insulin needs. Ucn2 gene transfer
could potentially provide tight glycemic control with a 1-time admin-
istration. Such an approach, if successful would add a new option for
use in a disease that is treated only with insulin, an agent that, despite
nearly 100 years of use, has considerable shortcomings.
MATERIALS AND METHODS
AAV8.Ucn2 Vector Production
An AAV8 vector encoding murine Ucn2 with a chicken b-actin
(CBA) promoter (Figure 1C) was produced as detailed previously.23
Plasmid pRep2/Cap8 was obtained from the University of Pennsylva-
nia Vector Core.
Animal Use
The Principles of Laboratory Animal Care (NIH publication no. 85–
23, revised 1985) were followed and the Animal Use and Care Com-
mittees of the VA San Diego Healthcare System approved the studies.
See Table S7 for summary of animal use. We used 222 male mice
(Jackson Laboratories, Bar Harbor, ME) including 108 heterozygous
Akita mice (C57BL/6J-Ins2Akita; age 10.1 ± 0.3 weeks, weight 20.7 ±
0.2 g) and 114 male C57BL/6J mice (age 10.1 ± 0.1 weeks, weight
25.6 ± 0.2 g). Nine C57BL/6J mice were excluded in the STZ study
due to failure to reach pre-specified hyperglycemia levels; 1 Akita
mouse died during anesthesia prior to treatment, and 19 Akita
mice died during the 7 month survival study (16 of 17 that received
saline; 3 of 17 that received Ucn2 gene transfer). Animal numbers
and additional information are included in figure legends and tables.
Mice were provided (ad libitum) a cereal-based diet (Harlan Teklad
Lab, Madison, WI, USA) for the entire study, regardless of interven-
tion. Duration of these studies ranges from 1.5–7.5 months and are
stipulated in the results. Mice were housed (20–21C) with lightsar Therapy: Methods & Clinical Development Vol. 17 June 2020 229
Molecular Therapy: Methods & Clinical Developmentoff from 6 PM to 6 AM daily. Food consumption and body weights
were recorded on 2- to 3-day intervals.
Streptozotocin Model of Insulin Deficiency
Normal male mice received 5 daily injections of STZ (50 mg/kg/d,
intraperitoneal, i.p.) following previously published reports for
induction of stable insulin deficient mice. These mice were used to
determine whether Ucn2 gene transfer was effective in a second
mouse model of insulin deficiency.22 Normal C57BL/6J male mice
that were given buffer but no STZ were simultaneously studied.
Three weeks after the final dose of STZ, glycemic indices were
obtained (12 h fasting glucose, glucose tolerance tests, HbA1c).
Mice then were assigned, based on their fasting glucose, to receive
i.v. AAV8.Ucn2 (n = 9) or saline (n = 8), such that the two groups
had similar pre-treatment mean fasting glucose levels. Mice that failed
to respond sufficiently to STZ (12 h fasting glucose <120 mg/dL) were
excluded from further study. Repeat glycemic indices were obtained
weekly for 4 weeks after randomization.
AAV8.Ucn2 Delivery
Under anesthesia (1.5% isoflurane via nose cone) a small incision was
made to expose the jugular vein for i.v. delivery. Mice were injected
with AAV8.Ucn2 or AAV8.Null (2  1013 gc/kg in 50 mL PBS) or
an equivalent volume of saline. Vector dose was 2  1013gc/kg, i.v.,
in all studies.
Glucose Tolerance Test
Mice were fasted for 12 h and received glucose (2 g/kg, i.p.). Blood
glucose levels were measured before and 30, 60, 90, and 120 min after
glucose injection. Blood was collected via a small tail incision and
glucose was measured using Contour Blood Glucose Meter via Blood
Glucose Test Strips (Bayer, Whippany NJ).
Hemoglobin A1c
HbA1c was measured in nonfasted mice using a DEC system.
Insulin Release
Fasted mice (12 h) received glucose (oral gavage, 2.5 mg/kg). Blood
before and sequentially after glucose delivery was taken for 2 h.
Plasma insulin was measured using insulin-specific ELISA.
Insulin Tolerance Test
Fasted mice (5 h) received insulin (0.75 units/kg, i.p.) and blood
glucose levels were measured before and 30, 60, 90, and 120 min later.
Hyperinsulinemic-Euglycemic Clamps
Hyperinsulinemic-euglycemic clamps were performed by the Van-
derbilt Mouse Metabolic Phenotyping Center to assess glucose
disposal rate, tissue glucose uptake, and hepatic glucose production.
Akita mice (2.5 months old, male) received AAV8.Ucn2 (n = 7) or
saline i.v. (n = 8). 4 months later, unrestrained mice underwent
hyperinsulinemic euglycemic clamp studies to quantitate glucose
disposal and insulin sensitivity, using a continuous insulin infusion
(4 mU/kg/min) in mice after 5 h fast.43230 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2Islet Insulin Release
Male C57BL/6J mice (25.6 ± 0.4 g; 2 months old) received i.v. sa-
line (n = 8) or i.v. AAV8.Ucn2 (2  1013 gc/kg, n = 8). 6 weeks
later, pancreata were perfused in situ with collagenase P digestion
solution (1.119 g/L collagenase P; Sigma, St. Louis MO) in Hank’s
balanced salt solution (HBSS, HyClone, Logan, UT), excised, di-
gested, washed with HBSS containing 0.3% BSA (Thermo Fisher,
San Diego CA) and 0.5 g dextrose (Thermo Fisher, San Diego
CA). Two pancreata were pooled so that there were 4 data points
per condition in each of the two groups. Purified islets from two
mice within each group were divided into two culture conditions
and cultured overnight (37C, 5% CO2) in RPMI 1640 (Waltham,
MA) without Ucn2 peptide or with 200 nM of Ucn2 peptide. On
day 2, a glucose-stimulated insulin secretion assay was performed.
100 islet equivalents (IEQ) were hand-picked and placed into a
12 mm Millicell cell culture insert (MilliporeSigma, Burlington,
MA), rinsed and incubated for 1 h (37C, 5% CO2) in 2.8 mM
glucose Krebs Buffer (0.115 M NaCl, 25 mM HEPES, 5 mM
KCl, 24 mM NaHCO3, 1 mM MgCl2, 2.5 mM CaCl2, pH 7.4) con-
taining no peptide or 200 nM Ucn2 peptide. The same 100 IEQ
islet Millicell was then transferred to fresh low glucose (2.8 mM)
Krebs buffer with or without Ucn2 peptide for 1 h (37C, 5%
CO2). Culture media were collected and stored at 20C. The
same islets then were transferred to high glucose (28 mM) Krebs
buffer with or without Ucn2 peptide for 1 h (37C, 5% CO2)
and culture media were collected and stored at 20C. Secreted
insulin was measured using Mercodia Mouse Insulin ELISA
(Uppsala, Sweden); media somatostatin was assessed using mouse
somatostatin ELISA (Ray Biotech, Peachtree Corner, GA).
Urocortin 2, Insulin, GLP-1, Glucagon, Triglyceride
Plasma Ucn2 was measured as previously reported,41 using a
mouse Ucn2 enzyme immunoassay kit (Kamiya Biomedical, Seattle
WA). Plasma insulin was measured using the mouse insulin
ELISA Kit (Crystal Chem, Downers Grove, IL). Fasting plasma
GLP-1 was measured by ELISA (Crystal Chem, Elk Grove Village,
IL). Fasting plasma glucagon concentrations were measured before
and 2 h after glucose stimulation (2.5 g/kg, oral) by an ELISA
(Crystal Chem, Downers Grove, IL). Random plasma triglyceride
was determined using a colorimetric/fluorometric kit (Biovision,
San Francisco CA).
Metabolic Studies
The Comprehensive Laboratory Animal Monitoring System
(CLAMS, Columbus Instruments, Columbus, OH) was used to
assess oxygen consumption and activity level in 12 male control
mice (C57BL/6J) and 12 male Akita mice. Half of each
group (n = 6) were randomized to receive AAV8.Ucn2 and
half received saline, and all underwent studies 8 weeks later.
Mice were kept in metabolic cages for 6.5 days (6 light, 7 dark cy-
cles) while measurements were continuously acquired.13 In addi-
tion, assessment of water intake, food consumption, and body
weight were conducted every 2–3 days for 8 weeks following
treatment.020
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Mice were anesthetized with ketamine (100 mg/kg, i.p.) and
xylazine (10 mg/kg, i.p.). Eyes were topically anesthetized
with 0.5% proparacaine (Bausch + Lomb, Rochester, NY) and
dilated with 1.5% tropicamide (Alcon Labs, Fort Worth, TX)
and 2.5% phenylephrine (Akorn, Lake Forest, IL). Anesthetized
animals were injected with 1% (w/v) fluorescein sodium (4 mL/g,
i.p.) and placed on an adjustable stage, so that the Micron
III (Phoenix Labs, Pleasanton, CA) objective could be stereoscopi-
cally adjusted to contact with the cornea through an ophthalmic
lubricant gel. Fluorescein angiographs were captured using a
filter with excitation (486 nm) and emission (536 nm) controlled
by a commercial software using the same acquisition parame-
ters for all mice. The vascular area (occupied by green fluores-
cence) was quantified in ImageJ. Retinal function was evaluated
through electroretinography (ERG) following established proto-
cols for mice.44 Mice were dark-adapted for 12 h and anesthetized
with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.).
Mice were given a dilating eye drop of 1.5% tropicamide
(Alcon Labs, Fort Worth, TX), 2.5% phenylephrine (Akorn,
Lake Forest, IL), and a drop of 0.5% proparacaine (Bausch +
Lomb, Rochester, NY) as analgesic. Mice were examined with a
full-field Ganzfeld bowl setup (Diagnosys, Lowell, MA), with
electrodes placed on each cornea, a subcutaneous ground
needle electrode placed in the tail, and a reference electrode
in the mouth (Grass Telefactor, West Warwick, RI). Lubricant
(Goniovisc 2.5%, HUB Pharmaceuticals, Rancho Cucamonga,
CA) was used to provide contact of the electrodes with
the eyes. Amplification (1–1,000 Hz bandpass, without notch
filtering), stimuli presentation, and data acquisition were
programmed and performed using the UTAS-E 3000
system (LKC Technologies, Gaithersburg, MD). For scotopic
ERG, the retina was stimulated with a xenon lamp at 2
and 0.5 log cd$s/m2. For photopic ERG, mice were adapted to
a background light of 1 log cd$s/m2, and light stimulation was
set at 1.5 log cd$s/m2. Recordings were collected and averaged in
manufacturer’s software (Veris, EDI, Milpitas, CA) and processed
in Microsoft Excel.
Kidney Function
Urine was collected for 3 h. Albumin concentration was determined
using an ELISA assay kit and creatinine concentration determined us-
ing a colorimetric assay kit (both from Abcam, Cambridge, MA).
Serum creatinine was measured using liquid chromatography tandem
mass spectrometry.
RT-PCR and Immunoblotting
RT-PCR and immunoblotting were conducted as previously
described.41 Skeletal muscle underwent evaluation of Akt and
AMPK activation using antibodies obtained from Cell Signaling
Technology (Danvers, MA): p-308-Akt (#4056), p-473-Akt (#4058),
total Akt (# 9272), p-172-AMPK (#2535), and GAPDH (# 51332S).
Antibody to vinculin was obtained from Sigma (St. Louis, MO;
SAB4200080).MoleculSelective Transcript Screening
Gene Array
Total RNA from liver and skeletal muscle was reverse-transcribed
into cDNA and amplified in PCR. Data shown are from insulin
signaling and glucose metabolism gene arrays (QIAGEN, German-
town, MD), which have 92 gene-specific primer sets in each 96-well
plate. Data are displayed only if: (1) >1.5-fold or <0.7-fold change
in mRNA (AAV8.Ucn2 versus AAV8.Null) or (2) p < 0.05 regardless
of fold-change. Skeletal muscle, liver, and pancreas mRNA expres-
sion. Skeletal muscle, liver, and pancreas RNA were isolated and
reverse transcribed into cDNA (Tables S3–S5). Genes of interest
were detected using their specific primers in qPCR. GAPDH was
used in each 96-well plate for an internal control during PCR. Results
were normalized to GAPDH and expressed as fold change. Data
in Tables S2–S5 are from 6 mice per group (AAV8.Null, n = 6;
AAV8.Ucn2, n = 6).
Necropsy and Histology
2-month-old male control mice received i.v. saline (n = 6) or i.v.
AAV8.Ucn2 (n = 6); age-matched male Akita mice received i.v.
AAV8.Null (n = 8) or i.v. AAV8.Ucn2 (n = 8). Mice were killed
3 months later (5 months of age) and underwent necropsy. Body,
liver, kidney, lung, and LV weight (including septum) and tibial
length were recorded. A short-axis midwall LV ring and samples of
liver, kidney, and pancreas were obtained and portions quickly frozen
in liquid nitrogen and stored at 80C or fixed in formalin and
embedded in paraffin. 5 mm sections were mounted and counter-
stained with H&E and with Masson’s trichrome and examined
for fibrosis and inflammation. To evaluate fibrosis of liver and trans-
mural LV, we scanned and quantified slides (Zeiss Axio Scan; Carl
Zeiss, Germany). Kidney histopathology was examined after Periodic
acid-Schiff (PAS) staining.
Finally, pancreatic islet number was assessed. Akita mice (2 months
old) received i.v. saline (n = 4) or i.v AAV8.Ucn2 (n = 4). Six weeks
later, pancreata were perfused in situ, imbedded in OCT, frozen
and sectioned (10 mm). Insulin was detected using rabbit anti-
insulin antibody (Abcam, Cambridge, MA), and donkey anti-rabbit
immunoglobulin G (IgG) secondary antibody (Alexa Fluor 488;
Thermo Scientific, San Diego, CA). Islets were counted and normal-
ized to area of tissue section (islets per mm2), and islet insulin
intensity using NIH ImageJ V1.52 software. Images were obtained
with a 20X objective at 488 nm and 509 nm excitation and emission
wavelengths, respectively, using a Zeiss Observer.Z1 microscope
(Carl Zeiss, Oberkochen, Germany), equipped with ApoTome.2
system.
Statistical Analysis
Analyses were performed using GraphPad Prism (GraphPad Soft-
ware, San Diego, CA). Treatment (Ucn2 gene transfer versus saline
or AAV8.Null) was randomized. Those collecting and analyzing
data obtained from physiological experiments and histological com-
parisons were blinded to group identity. One scientist not involved
in the study recorded group/treatment identity. Once unblinded, noar Therapy: Methods & Clinical Development Vol. 17 June 2020 231
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estimated based on the mean coefficient of variation of key efficacy
endpoints (20%) and desired detectability threshold (40%). Power
calculations assumed a b-error of 0.10 (90% power) and an a-error
of <0.05. The mean group size was n = 7. Statistical tests for each
experiment are described in figure legends. Data represent mean ±
SE; group differences were tested for significance using Student’s t
test (unpaired, two-tailed), repeated-measures ANOVA or two-way
ANOVA.Whenmultiple tests weremade on the same dataset, correc-
tions were made, as indicated. In glucose tolerance tests, the trape-
zoidal rule was applied to determine area under the curve (AUC).
The null hypothesis was rejected when p < 0.05. Akita mice and
mice rendered insulin deficient by STZ both have a stronger pheno-
type in male versus female mice, which necessitated our use of male
mice. Groups were composed of animals of similar age, weight, and
absence of confounding diseases. The AAV vectors used were made
at the University of Pennsylvania Vector Core. Plasmids underwent
tests to determine: concentration, A260/280 ratio, detection
of endotoxin, and plasmid identity. Real-time PCR was used to
determine genome copies to assess AAV particles with full genome
content. Vectors were sequenced and purity determined by
electrophoresis.
Data Availability
The datasets generated during and/or analyzed during the current
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request.
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